MGMT and glioblastoma: Given the undeniable role of PGRN in the clinical course of GBM, the combined evaluation of PGRN expression level along with typical GBM-associated biomarkers (e.g., IDH mutations, 1p19q deletion or MGMT promoter methylation) could probably provide strong prognostic factors in predicting the clinical outcomes of this tumour type.